Specialty pharmaceutical company EUSA Pharma of Oxford, U.K., has entered into a definitive agreement to acquire biopharmaceutical firm Cytogen for $22.6 million.
Under the terms of the proposed cash transaction, Cytogen shareholders will receive 62¢ per share of stock. Cytogen's board has given its blessing to the agreement and will recommend its approval to shareholders.
Upon completion of the transaction, EUSA intends to apply to delist all of the company's shares from the Nasdaq stock exchange.
Cytogen's revenues totaled $20.2 million in 2007. The Princeton, NJ-based company reporting a net loss of $25.7 million last year.
EUSA Pharma specializes in licensing, developing, and marketing late-stage oncology, pain control, and critical care products. The company currently has six products on the market, including the antibiotic surgical implant Collatamp G, Erwinase, and Kidrolase for the treatment of acute lymphoblastic leukemia. Rapydan is a rapid-onset anesthetic patch, which recently received European marketing approval.
EUSA Pharma also has raised more than $50 million in investment fundraising. The investment round, which is conditional on the completion of the Cytogen acquisition, is led by German venture capital firm TVM Capital and supported by EUSA's existing investors.
Related Reading
Cytogen taps new chief executive, November 12, 2007
Cytogen receives Nasdaq notice, November 6, 2007
Cytogen to raise $10 million, July 2, 2007
Cytogen hires new executive, June 11, 2007
Cytogen sales grow, loss narrows, May 11, 2007
Copyright © 2008 AuntMinnie.com
![Overview of the study design. (A) The fully automated deep learning framework was developed to estimate body composition (BC) (defined as subcutaneous adipose tissue [SAT] in liters; visceral adipose tissue [VAT] in liters; skeletal muscle [SM] in liters; SM fat fraction [SMFF] as a percentage; and intramuscular adipose tissue [IMAT] in deciliters) from MRI. The fully automated framework comprised one model (model 1) to quantify different BC measures (SAT, VAT, SM, SMFF, and IMAT) as three-dimensional (3D) measures from whole-body MRI scans. The second model (model 2) was trained to identify standardized anatomic landmarks along the craniocaudal body axis (z coordinate field), which allowed for subdividing the whole-body measures into different subregions typically examined on clinical routine MRI scans (chest, abdomen, and pelvis). (B) BC was quantified from whole-body MRI in over 66,000 individuals from two large population-based cohort studies, the UK Biobank (UKB) (36,317 individuals) and the German National Cohort (NAKO) (30,291 individuals). Bar graphs show age distribution by sex and cohort. BMI = body mass index. (C) After the performance assessment of the fully automated framework, the change in BC measures, distributions, and profiles across age decades were investigated. Age-, sex-, and height-adjusted body composition reference curves were calculated and made publicly available in a web-based z-score calculator (https://circ-ml.github.io).](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/05/body-comp.XgAjTfPj1W.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
